Ber, Suzan https://orcid.org/0000-0003-4219-6032
Yang, Ming
Sciacovelli, Marco
Samarajiwa, Shamith
Patel, Khushali
Nikitopoulou, Efterpi
Howitt, Annie
Cook, Simon J
Venkitaraman, Ashok R https://orcid.org/0000-0002-6876-2672
Frezza, Christian https://orcid.org/0000-0002-3293-7397
Esposito, Alessandro https://orcid.org/0000-0002-5051-091X
Funding for this research was provided by:
Cancer Research UK (C54674/A27487)
Cancer Research UK (C51061/A27453)
cambridgeuniversity | Cancer Research UK Cambridge Institute, University of Cambridge (C9685/A25117,C9685/A28397)
UKRI | Medical Research Council (MC_UU_12022/1 and MC_UU_12022/8)
UKRI | Medical Research Council (MRC_MC_UU_12022/6)
EC | Horizon 2020 Framework Programme (101135034 (UKRI #10107542))
EC | Horizon 2020 Framework Programme (101073507)
EC | ERC | HORIZON EUROPE European Research Council (ERC819920)
UKRI | Biotechnology and Biological Sciences Research Council (BB/J004456/1,BB/P013384/1 and BB/Y006925/1)
Alexander von Humboldt-Stiftung (n/a)
Article History
Received: 18 June 2025
Revised: 27 October 2025
Accepted: 3 November 2025
First Online: 20 November 2025
Disclosure and competing interests statement
: ARV serves on the scientific advisory board of Chugai Pharmaceuticals (Japan), and is a co-founder of PhoreMost (UK) and Sentinel Oncology (UK).